Part of the
Stem Cell Revolution

Stem cells are expected to revolutionize the treatment of today's severe and incurable diseases. NextCell develops pioneering stem cell therapies for the treatment of autoimmune and inflammatory diseases as well as for use in organ transplants.

Technology

NextCell develops ProTrans™, a drug candidate consisting of stem cells for the treatment of autoimmune diseases, initially focusing on type- 1 diabetes. ProTrans is based on NextCell patent pending Selection Algorithm. Further, NextCell runs Cellaviva, Nordic's largest private stem cell bank, approved by IVO.
Read more

ProTrans shows significant effect in Diabetes

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).

Read more

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from umbilical cord. NextCell is focusing on research and development of novel stem cell therapies and is also running a tissue establishment and primary biobank, classified as healthcare provider.
Read more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Read our latest report:
Q3 Report, 2019/2020
Download

News

2020-10-21

ProTrans stem cells approved for clinical trials in COVID-19 patients

NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19 patients with the drug candidate ProTrans has been approved by both the Ethics Committy and the Swedish Medical Product Agency. The study will be conducted at the University Hospital in Örebro in c...
Read more
2020-10-14

NextCell presents at “Investerarjakten”

NextCell Pharma AB (“NextCell”) will today at 15:00 present at Investerarjakten. Viewers have the possibility to ask questions directly to CEO Mathias Svahn. The event is broadcast live on Studio Direct's youtube channel, the facebook group Aktier and on Investerarbrevet.se between 13:00-17:00. ...
Read more
2020-09-10

Presentation of the positive results from ProTrans-2

NextCell Pharma AB ("NextCell") announced earlier this week that the clinical diabetes trial ProTrans-2 had met the primary endpoints. On the occation of that, the principal investigator Professor Per-Ola Carlsson together with NextCell will hold a webcast presentation today, Thursday 10 Septembe...
Read more
2020-09-08

ProTrans shows significant effect in Diabetes

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value...
Read more
All news